aTYR PHARMA INC (ATYR) Current Ratio
- Current ratio · latest quarter: Value 5.12×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 5.12× | Current assets / current liabilities. $58.36M ÷ $11.40M ≈ 5.12× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 58.36M USD | Assets, Current |
| Current obligations | 11.40M USD | Liabilities, Current |
| Cash and equivalents | 16.16M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 41.26M USD | Marketable Securities, Current · Debt Securities, Available-for-sale, Current |
| Customer receivables | (m) | |
| Inventory | (m) | |
| Payables | 3.24M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) | Long-term Debt, Current Maturities |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $58.36M | $11.40M | $16.16M | $41.26M | (m) | (m) | $3.24M | (m) | 5.12× |
| 2026-03-31 | $67.58M | $11.70M | $10.01M | $56.51M | (m) | (m) | $2.75M | (m) | 5.78× |
| 2025-12-31 | $80.24M | $15.15M | $10.74M | $67.94M | (m) | (m) | $3.89M | (m) | 5.30× |
| 2025-09-30 | $93.01M | $15.68M | $6.15M | $84.05M | (m) | (m) | $4.06M | (m) | 5.93× |
| 2025-06-30 | $87.49M | $15.53M | $17.22M | $63.13M | (m) | (m) | $3.88M | (m) | 5.63× |
| 2025-03-31 | $83.27M | $10.68M | $10.36M | $65.99M | (m) | (m) | $1.53M | (m) | 7.79× |
| 2024-12-31 | $81.95M | $14.97M | $11.05M | $61.07M | (m) | (m) | $4.32M | (m) | 5.48× |
| 2024-09-30 | $76.32M | $14.12M | $11.46M | $54.53M | (m) | (m) | $3.95M | (m) | 5.41× |
| 2024-06-30 | $90.30M | $11.84M | $6.80M | $71.68M | (m) | (m) | $1.25M | (m) | 7.63× |
| 2024-03-31 | $96.92M | $15.98M | $6.81M | $77.69M | (m) | (m) | $4.89M | (m) | 6.07× |
| 2023-12-31 | $102.99M | $16.42M | $22.54M | $75.62M | (m) | (m) | $3.53M | (m) | 6.27× |
| 2023-09-30 | $107.30M | $12.88M | $9.79M | $92.34M | (m) | (m) | $2.04M | (m) | 8.33× |
| 2023-06-30 | $114.43M | $12.37M | $12.31M | $96.27M | (m) | (m) | $516.00K | (m) | 9.25× |
| 2023-03-31 | $119.45M | $13.65M | $20.69M | $93.69M | (m) | (m) | $3.96M | (m) | 8.75× |
| 2022-12-31 | $80.87M | $13.86M | $9.98M | $56.16M | (m) | (m) | $3.11M | (m) | 5.83× |
| 2022-09-30 | $84.63M | $11.21M | $18.36M | $59.02M | (m) | (m) | $3.13M | (m) | 7.55× |
| 2022-06-30 | $93.36M | $9.26M | $8.48M | $80.07M | (m) | (m) | $1.67M | (m) | 10.08× |
| 2022-03-31 | $103.12M | $6.27M | $8.32M | $90.34M | (m) | (m) | $1.56M | (m) | 16.45× |
| 2021-12-31 | $113.57M | $6.01M | $2.34M | $105.58M | (m) | (m) | $1.03M | (m) | 18.89× |
| 2021-09-30 | $121.57M | $5.82M | $59.74M | $56.61M | (m) | (m) | $900.00K | (m) | 20.89× |
| 2021-06-30 | $46.41M | $7.28M | $2.19M | $41.87M | (m) | (m) | $2.22M | (m) | 6.37× |
| 2021-03-31 | $52.13M | $4.45M | $12.59M | $38.05M | (m) | (m) | $1.16M | (m) | 11.71× |
| 2020-12-31 | $35.53M | $5.86M | $16.95M | $14.74M | (m) | (m) | $1.43M | (m) | 6.06× |
| 2020-09-30 | $38.22M | $8.03M | $18.15M | $18.00M | (m) | (m) | $1.35M | $3.06M | 4.76× |
| 2020-06-30 | $43.84M | $9.80M | $21.63M | $19.80M | (m) | (m) | $603.00K | $4.98M | 4.47× |
| 2020-03-31 | $50.37M | $10.45M | $39.45M | $10.38M | (m) | (m) | $748.00K | $6.87M | 4.82× |
| 2019-12-31 | $31.93M | $12.92M | $9.21M | $21.93M | (m) | (m) | $847.00K | $8.74M | 2.47× |
| 2019-09-30 | $39.14M | $11.83M | $17.34M | $20.72M | (m) | (m) | $1.32M | $7.84M | 3.31× |
| 2019-06-30 | $43.87M | $11.30M | $14.51M | $27.89M | (m) | (m) | $664.00K | $7.82M | 3.88× |
| 2019-03-31 | $44.74M | $11.18M | $12.96M | $30.05M | (m) | (m) | $834.00K | $7.79M | 4.00× |
| 2018-12-31 | $50.80M | $10.83M | $22.96M | $26.58M | (m) | (m) | $1.04M | $7.77M | 4.69× |
| 2018-09-30 | $57.65M | $10.72M | $31.55M | $24.41M | (m) | (m) | $599.00K | $7.74M | 5.38× |
| 2018-06-30 | $66.00M | $11.08M | $19.27M | $45.06M | (m) | (m) | $832.00K | $7.72M | 5.95× |
| 2018-03-31 | $76.01M | $11.02M | $21.94M | $52.16M | (m) | (m) | $1.46M | $7.03M | 6.90× |
| 2017-12-31 | $86.98M | $10.39M | $21.09M | $64.03M | (m) | (m) | $2.28M | $5.01M | 8.37× |
| 2017-09-30 | $92.21M | $9.72M | $29.77M | $60.62M | (m) | (m) | $3.59M | $2.27M | 9.49× |
| 2017-06-30 | $59.10M | $9.65M | $35.91M | $21.31M | (m) | (m) | $2.67M | $2.79M | 6.12× |
| 2017-03-31 | $63.78M | $6.55M | $28.90M | $33.03M | (m) | (m) | $1.25M | $1.09M | 9.74× |
| 2016-12-31 | $74.77M | $8.53M | $38.39M | $33.76M | (m) | (m) | $2.61M | $339.00K | 8.77× |
| 2016-09-30 | $73.65M | $11.94M | $34.33M | $36.20M | (m) | (m) | $3.56M | (m) | 6.17× |
| 2016-06-30 | $85.89M | $13.92M | $43.19M | $40.73M | (m) | (m) | $4.72M | (m) | 6.17× |
| 2016-03-31 | $87.62M | $13.19M | $54.10M | (m) | (m) | (m) | $5.88M | (m) | 6.64× |
| 2015-12-31 | $97.95M | $12.15M | $53.02M | $42.51M | (m) | (m) | $3.87M | $3.37M | 8.06× |
| 2015-09-30 | $111.38M | $8.78M | $60.05M | (m) | (m) | (m) | $1.59M | (m) | 12.69× |
| 2015-06-30 | $106.17M | $9.37M | $63.07M | (m) | (m) | (m) | $3.00M | (m) | 11.33× |
| 2015-03-31 | $55.17M | $11.54M | $54.51M | $0.00 | (m) | (m) | $3.17M | (m) | 4.78× |
| 2014-12-31 | $16.51M | $10.11M | $13.90M | (m) | (m) | (m) | $1.43M | (m) | 1.63× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B |